Answers are grounded in this paper and cite their sources.
Demonstrates that targeting the C5a/C5aR1 pathway suppresses glioblastoma growth and macrophage interaction.
Tumor-associated macrophages (TAMs) symbiotically interact with glioma stem cells (GSCs) to facilitate GSCs stemness maintenance and glioblastoma (GBM) progression. Here we identified the complement 5a (C5a) as a key mediator of GSCs-TAMs symbiosis through integrative screening. C5a is preferentially expressed and secreted by GSCs. C5a activates the p-STAT3-cMyc-PD-L1 axis to promote GSCs proliferation, self-renewal and resistance against cytotoxic T cells through its receptor C5aR1. Moreover, GSCs-derived C5a trigger the infiltration and immunosuppressive polarization of TAMs through C5aR1-p-AKT T308 axis in tumor microenvironment. Importantly, silencing or pharmacological inhibition of C5a/C5aR1 disrupts both GSCs and TAMs and suppresses GBM tumor growth. In human GBM, the C5a/C5aR1 axis is activated and positively correlates with stemness, immunosuppressive TAMs and predicts poor prognosis. Collectively, these results demonstrate the key role of C5a/C5aR1 pathway in GSCs-TAMs symbiosis and indicate the therapeutic potential of targeting this pathway for GBM treatment.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: